Cytyc Announces That Its Unconditional, A$3.25 Cash Offer Will Remain Open until 17 November 2006

  
    
  
  
    
      Cytyc Corporation (Nasdaq: CYTC) today announced that its unconditional 
      A$3.25 cash per share tender offer to acquire Vision Systems Limited 
      (ASX: VSL), dispatched to Vision Systems shareholders on 2 October 2006, 
      will remain open for Vision Systems shareholders to accept until 17 
      November 2006, unless withdrawn or extended further in accordance with 
      the Australian Corporations Act.
    
    
      Vision Systems shareholders who accept its unconditional A$3.25 cash 
      offer will receive cash for their securities within five days of 
      accepting Cytyc's offer.
    
    
      ABOUT CYTYC CORPORATION
    
    
      Cytyc Corporation is a leading provider of best-in-class medical 
      technology that enables physicians and laboratories to improve patient's 
      lives throughout the world. Cytyc provides diagnostic and minimally 
      invasive surgical products targeting cancer and women's health. The 
      ThinPrep® System is 
      the most widely used method for cervical cancer screening in the United 
      States. The ThinPrep System consists of the ThinPrep® 
      2000 Processor, ThinPrep®3000 
      Processor, ThinPrep® 
      Imaging System, and related reagents, filters, and other supplies. The 
      ThinPrep System also provides the platform from which the Company 
      launched its expansion into breast cancer risk assessment with the 
      FirstCyte® Breast 
      Test. The MammoSite® 
      Radiation Therapy System is a single-use device for the treatment of 
      breast cancer that positions radiation sources directly into the 
      post-lumpectomy site to optimize radiation treatment delivery while 
      minimizing damage to healthy tissue. The NovaSure® 
      Impedance Controlled Endometrial Ablation System, or the NovaSure® 
      System, is an innovative endometrial ablation device to treat 
      menorrhagia, or excessive menstrual bleeding.
    
    
      Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC. Cytyc, 
      ThinPrep, NovaSure, MammoSite, and GliaSite are registered trademarks of 
      Cytyc Corporation.
    
    
      ABOUT VISION SYSTEMS LIMITED
    
    
      Vision Systems operates two core business units: Vision Bio-Systems 
      manufactures and markets automated instruments and reagents for 
      biopsy-based detection of cancer and infectious diseases in pathology 
      laboratories worldwide. Products include the Bond™-maX 
      advanced staining system, the Peloris™ tissue 
      processor, and Novocastra™ antibodies and 
      biochemical reagents. Income is generated from capital equipment sales, 
      visualization reagents to the Bond system and Novocastra branded 
      antibodies used in immunohistochemistry for the identification of cancer 
      and infectious diseases.
    
    
      The second business unit is Invetech, a worldwide provider of research 
      and development services for both internal and external clients, 
      primarily in the international healthcare sector.
    
    
      FORWARD LOOKING STATEMENTS
    
    
      Forward-looking statements in this press release are made pursuant to 
      the provisions of Section 21E of the Securities Exchange Act of 1934. 
      Investors are cautioned that statements in this press release which are 
      not strictly historical statements, including, without limitation, 
      statements relating to Cytyc's future financial condition, operating 
      results and economic performance, and management's expectations 
      regarding key customer relationships, future growth opportunities, 
      product acceptance and business strategy, constitute forward-looking 
      statements. These statements are based on current expectations, 
      forecasts and assumptions that are subject to risks and uncertainties, 
      which could cause actual outcomes and results to differ materially from 
      those statements. Risks and uncertainties include, among others, 
      dependence on key personnel and customers as well as reliance on 
      proprietary technology, uncertainty of product development efforts and 
      product acceptance, management of growth, product diversification, and 
      organizational change, entry into new market segments domestically and 
      new markets internationally, risks associated with litigation, the 
      effective integration of acquired businesses and technologies, 
      competition and competitive pricing pressures, risks associated with the 
      FDA regulatory approval processes and healthcare reimbursement policies 
      in the United States and abroad, introduction of technologies that are 
      disruptive to Cytyc's business and operations, the impact of new 
      accounting requirements and governmental rules and regulations, as well 
      as other risks detailed in Cytyc's filings with the Securities and 
      Exchange Commission, including those under the heading "Risk Factors" in 
      its 2005 Annual Report on Form 10-K and its most recent Quarterly Report 
      on Form 10-Q filed with the Commission. Cytyc cautions readers not to 
      place undue reliance on any such forward-looking statements, which speak 
      only as of the date they were made. Cytyc disclaims any obligation to 
      publicly update or revise any such statements to reflect any change in 
      its expectations or events, conditions, or circumstances on which any 
      such statements may be based, or that may affect the likelihood that 
      actual results will differ from those set forth in the forward-looking 
      statements.
    
  
Cytyc Corporation (Nasdaq: CYTC) today announced that its
unconditional A$3.25 cash per share tender offer to acquire Vision
Systems Limited (ASX: VSL), dispatched to Vision Systems shareholders
on 2 October 2006, will remain open for Vision Systems shareholders to
accept until 17 November 2006, unless withdrawn or extended further in
accordance with the Australian Corporations Act.

   Vision Systems shareholders who accept its unconditional A$3.25
cash offer will receive cash for their securities within five days of
accepting Cytyc's offer.

   ABOUT CYTYC CORPORATION

   Cytyc Corporation is a leading provider of best-in-class medical
technology that enables physicians and laboratories to improve
patient's lives throughout the world. Cytyc provides diagnostic and
minimally invasive surgical products targeting cancer and women's
health. The ThinPrep(R) System is the most widely used method for
cervical cancer screening in the United States. The ThinPrep System
consists of the ThinPrep(R) 2000 Processor, ThinPrep(R)3000 Processor,
ThinPrep(R) Imaging System, and related reagents, filters, and other
supplies. The ThinPrep System also provides the platform from which
the Company launched its expansion into breast cancer risk assessment
with the FirstCyte(R) Breast Test. The MammoSite(R) Radiation Therapy
System is a single-use device for the treatment of breast cancer that
positions radiation sources directly into the post-lumpectomy site to
optimize radiation treatment delivery while minimizing damage to
healthy tissue. The NovaSure(R) Impedance Controlled Endometrial
Ablation System, or the NovaSure(R) System, is an innovative
endometrial ablation device to treat menorrhagia, or excessive
menstrual bleeding.

   Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC.
Cytyc, ThinPrep, NovaSure, MammoSite, and GliaSite are registered
trademarks of Cytyc Corporation.

   ABOUT VISION SYSTEMS LIMITED

   Vision Systems operates two core business units: Vision
Bio-Systems manufactures and markets automated instruments and
reagents for biopsy-based detection of cancer and infectious diseases
in pathology laboratories worldwide. Products include the Bond(TM)-maX
advanced staining system, the Peloris(TM) tissue processor, and
Novocastra(TM) antibodies and biochemical reagents. Income is
generated from capital equipment sales, visualization reagents to the
Bond system and Novocastra branded antibodies used in
immunohistochemistry for the identification of cancer and infectious
diseases.

   The second business unit is Invetech, a worldwide provider of
research and development services for both internal and external
clients, primarily in the international healthcare sector.

   FORWARD LOOKING STATEMENTS

   Forward-looking statements in this press release are made pursuant
to the provisions of Section 21E of the Securities Exchange Act of
1934. Investors are cautioned that statements in this press release
which are not strictly historical statements, including, without
limitation, statements relating to Cytyc's future financial condition,
operating results and economic performance, and management's
expectations regarding key customer relationships, future growth
opportunities, product acceptance and business strategy, constitute
forward-looking statements. These statements are based on current
expectations, forecasts and assumptions that are subject to risks and
uncertainties, which could cause actual outcomes and results to differ
materially from those statements. Risks and uncertainties include,
among others, dependence on key personnel and customers as well as
reliance on proprietary technology, uncertainty of product development
efforts and product acceptance, management of growth, product
diversification, and organizational change, entry into new market
segments domestically and new markets internationally, risks
associated with litigation, the effective integration of acquired
businesses and technologies, competition and competitive pricing
pressures, risks associated with the FDA regulatory approval processes
and healthcare reimbursement policies in the United States and abroad,
introduction of technologies that are disruptive to Cytyc's business
and operations, the impact of new accounting requirements and
governmental rules and regulations, as well as other risks detailed in
Cytyc's filings with the Securities and Exchange Commission, including
those under the heading "Risk Factors" in its 2005 Annual Report on
Form 10-K and its most recent Quarterly Report on Form 10-Q filed with
the Commission. Cytyc cautions readers not to place undue reliance on
any such forward-looking statements, which speak only as of the date
they were made. Cytyc disclaims any obligation to publicly update or
revise any such statements to reflect any change in its expectations
or events, conditions, or circumstances on which any such statements
may be based, or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements.